专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明授权

US5167956A Immunotoxin with in-vivo T cell suppressant activity 失效
标题翻译：具有免疫抑制剂活性的免疫细胞毒素
公开(公告)号：US5167956A
公开(公告)日：1992-12-01
申请号：US653164
申请日：1991-02-11
申请人： David M. Neville, Jr. , Joshua E. Scharff
发明人： David M. Neville, Jr. , Joshua E. Scharff
IPC分类号： A61K38/00 , A61K47/48 , C07K14/705 , C07K16/00
CPC分类号： A61K47/48561 , A61K47/48438 , C07K14/705 , C07K16/00 , A61K38/00 , C07K2319/00 , C07K2319/33 , C07K2319/55
摘要： The present invention relates to an immunotoxin. The invention further relates to a method of treating T cell leukemias and lymphomas, graft-versus-host diseases, and autoimmune diseases by administering an immunotoxin.
摘要翻译：本发明涉及免疫毒素。本发明还涉及通过施用免疫毒素来治疗T细胞白血病和淋巴瘤，移植物抗宿主病和自身免疫性疾病的方法。

62. 发明授权

US5112607A Potentiation of immunotoxin action by Brefeldin A 失效
标题翻译： Brefeldin A的免疫毒素作用的增强
公开(公告)号：US5112607A
公开(公告)日：1992-05-12
申请号：US715094
申请日：1991-06-05
申请人： Thomas H. Hudson , Michael A. King
发明人： Thomas H. Hudson , Michael A. King
IPC分类号： A61K39/395 , A61K47/48
CPC分类号： A61K47/48438 , A61K39/395
摘要： A method of potentiating immunotoxin action in an immunotoxin/target-cell stem in which Brefeldin A is utilized as an immunopotentiator. The Brefeldin A enhances the immunotoxin pathway while blocking or inhibiting the nonspecific pathway, thus being particularly useful in conjunction with immunotoxins made from holotoxins. The Brefeldin A is effective in small, nontoxic concentrations and therefore may be utilized with either in vivo or in vitro systems.
摘要翻译：在其中使用布雷菲德菌素A作为免疫增强剂的免疫毒素/靶细胞系统中增强免疫毒素作用的方法。布雷菲德菌素A增强免疫毒素途径，同时阻断或抑制非特异性途径，因此特别适用于由全毒素制成的免疫毒素。布雷菲德菌素A在小的无毒浓度下有效，因此可以与体内或体外系统一起使用。

63. 发明授权

US4767621A Drugs comprising in association at least one immunotoxin and at least one monovalent carboxylic ionophore 失效
标题翻译：包含至少一种免疫毒素和至少一种一价羧酸离子载体的药物
公开(公告)号：US4767621A
公开(公告)日：1988-08-30
申请号：US650570
申请日：1984-09-14
申请人： Franz Jansen , Pierre Gros
发明人： Franz Jansen , Pierre Gros
IPC分类号： A61K39/44 , A61K45/06 , A61K47/48 , A61P35/00 , A61K39/00 , C07K13/00
CPC分类号： A61K47/48438 , Y10S530/828
摘要： The present invention relates to drugs characterized in that they comprise, in association, at least one immunotoxin and at least one monovalent carboxylic ionophore.
摘要翻译：本发明涉及药物，其特征在于它们包括至少一种免疫毒素和至少一种一价羧酸离子载体。

64. 发明授权

US4162303A Potency and atoxicity test for modified neurotoxin 失效
标题翻译：改性神经毒素的效力和毒性试验
公开(公告)号：US4162303A
公开(公告)日：1979-07-24
申请号：US807654
申请日：1977-06-17
申请人： Murray J. Sanders
发明人： Murray J. Sanders
IPC分类号： A61K47/48 , G01N33/15 , G01N33/50 , A61K29/00 , A61K35/58 , C12K9/00
CPC分类号： G01N33/5008 , A61K47/48438
摘要： A method for proving the potency and atoxicity of modified neurotoxin is provided. A thin sheet of viable cells is provided on a growth substrate. Viability of the sheet of cells is defined as exhibiting an uninhibited growth potential of at least 10.sup.6 Plaque Forming Units of Semliki Forest virus. The sheet of cells is treated with the test modified neurotoxin and then inoculated with the Semliki Forest virus. The reduction in the number of plaques of Semliki Forest virus in the culture indicates the potency of the modified neurotoxin, since the modified neurotoxin interferes with plaque formation by the Semliki Forest virus in proportion to its potency. Atoxicity of the modified neurotoxin is demonstrated by lack of cell destruction.
摘要翻译：提供了证明改性神经毒素的效力和毒性的方法。在生长基质上提供薄的活细胞。细胞片的活力定义为表现出至少106个塞米利奇森林病毒斑块形成单位的未抑制的生长势。用测试的修饰的神经毒素处理细胞片，然后用Semliki Forest病毒接种。文化中Semliki Forest病毒斑块数量的减少表明改性神经毒素的效力，因为改良的神经毒素会干扰Semliki Forest病毒与其效力成比例的斑块形成。修饰的神经毒素的毒性由缺乏细胞破坏证明。

65. 发明授权

US09169470B2 Methods and compositions for generating bioactive assemblies of increased complexity and uses 有权
公开(公告)号：US09169470B2
公开(公告)日：2015-10-27
申请号：US14488921
申请日：2014-09-17
申请人： IBC Pharmaceuticals, Inc.
发明人： Chien-Hsing Chang , David M. Goldenberg , William J. McBride , Edmund A. Rossi
IPC分类号： A61K47/48 , C07K16/28 , C12N9/12 , C12N9/96 , A61K31/00 , B82Y5/00 , B82Y10/00 , B82Y15/00 , C07K16/30 , G01N33/543 , G01N33/58 , C07K14/475 , A61K38/00 , A61K39/00
CPC分类号： A61K47/48438 , A61K31/00 , A61K38/00 , A61K47/48415 , A61K47/48484 , A61K47/485 , A61K47/48538 , A61K47/48546 , A61K47/48561 , A61K47/48569 , A61K47/6811 , A61K47/6817 , A61K47/6829 , A61K47/6833 , A61K47/6843 , A61K47/6845 , A61K47/6849 , A61K47/6851 , A61K2039/505 , B82Y5/00 , B82Y10/00 , B82Y15/00 , C07K14/475 , C07K16/18 , C07K16/22 , C07K16/28 , C07K16/2803 , C07K16/2833 , C07K16/2851 , C07K16/2863 , C07K16/2881 , C07K16/2887 , C07K16/2896 , C07K16/3007 , C07K16/3092 , C07K16/32 , C07K2317/31 , C07K2317/55 , C07K2317/76 , C07K2319/30 , C07K2319/35 , C07K2319/70 , C07K2319/74 , C12N9/12 , C12N9/22 , C12N9/96 , C12Y207/11001 , G01N33/54353 , G01N33/588 , Y02A50/491
摘要： The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition.

66. 发明申请

US20150284425A1 Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis 审中-公开
标题翻译：有效和高效的细胞毒性肽及其抗体 - 药物结合物及其合成
公开(公告)号：US20150284425A1
公开(公告)日：2015-10-08
申请号：US14515807
申请日：2014-10-16
申请人： Shanghui Hu , Lucy Xiumin Zhao , Jinying Ning , Xufang Tian
发明人： Shanghui Hu , Lucy Xiumin Zhao , Jinying Ning , Xufang Tian
IPC分类号： C07K5/02 , C07K7/02 , A61K47/48
CPC分类号： C07K5/0207 , A61K38/00 , A61K47/48438 , A61K47/6817 , A61K47/6851 , A61K47/6889 , C07K5/0205 , C07K5/06052 , C07K7/02
摘要： The present invention provides a family of novel cytotoxic pentapeptides, which show potent antitumor activities against several cancer lines. The antibody-drug conjugates prepared from those pentapeptides can efficiently kill cancer cells.
摘要翻译：本发明提供了一种新的细胞毒性五肽家族，其对几种癌细胞系显示出有效的抗肿瘤活性。从这些五肽制备的抗体 - 药物偶联物可以有效地杀死癌细胞。

67. 发明申请

US20150023988A1 POTENT AND SELECTIVE INHIBITORS OF NAV1.7 有权
标题翻译： NAV1.7的POTENT和选择性抑制剂
公开(公告)号：US20150023988A1
公开(公告)日：2015-01-22
申请号：US14207445
申请日：2014-03-12
申请人： AMGEN INC.
发明人： Justin K. MURRAY , Jerry Ryan HOLDER , Malgorzata WANSKA , Christopher M. TEGLEY , James R. FALSEY , Elizabeth M. DOHERTY , Leslie P. MIRANDA
IPC分类号： A61K47/48 , C07K16/00 , A61K38/17 , C07K14/435
CPC分类号： A61K47/48438 , A61K38/00 , A61K47/60 , A61K47/68 , A61K47/6817 , C07K14/43518 , C07K14/705 , C07K16/44
摘要： Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Nav1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.
摘要翻译：公开了包含分离的多肽的物质组合物，其是外周限制的Nav1.7抑制剂。在一些公开的实施方案中，分离的多肽是Nav1.7的抑制剂。其它实施方案是本发明组合物和包含本发明组合物的药物组合物的共轭实施方案。公开了编码本发明多肽和表达载体的一些实施方案的分离的核酸，以及含有它们的重组宿主细胞。还公开了治疗或预防疼痛的方法。

68. 发明授权

US08911732B2 Anti-mesothelin antibodies and immunoconjugates 有权
标题翻译：抗间皮素抗体和免疫缀合物
公开(公告)号：US08911732B2
公开(公告)日：2014-12-16
申请号：US13330414
申请日：2011-12-19
申请人： Mark Dennis , Suzanna J. Scales , Susan D. Spencer , Yin Zhang
发明人： Mark Dennis , Suzanna J. Scales , Susan D. Spencer , Yin Zhang
IPC分类号： A61K39/44 , A61K51/10 , C07K16/30 , A61K47/48 , C07K16/28 , A61K39/00
CPC分类号： A61K47/6851 , A61K31/7068 , A61K38/08 , A61K39/39558 , A61K45/06 , A61K47/48438 , A61K47/48569 , A61K47/48638 , A61K47/6803 , A61K47/6849 , A61K51/1027 , A61K2039/505 , A61K2039/507 , C07K16/28 , C07K16/30 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/574 , G01N33/57423 , G01N33/57438 , G01N33/57442 , G01N33/57449 , G01N2333/705
摘要： The invention provides anti-mesothelin antibodies and immunoconjugates and methods of using the same.
摘要翻译：本发明提供抗间皮素抗体和免疫缀合物及其使用方法。

69. 发明授权

US08246960B2 Methods and compositions for generating bioactive assemblies of increased complexity and uses 有权
标题翻译：用于生成增加复杂性和用途的生物活性组件的方法和组合物
公开(公告)号：US08246960B2
公开(公告)日：2012-08-21
申请号：US13021302
申请日：2011-02-04
申请人： Chien-Hsing Chang , David M. Goldenberg , William J. McBride , Edmund A. Rossi
发明人： Chien-Hsing Chang , David M. Goldenberg , William J. McBride , Edmund A. Rossi
IPC分类号： A61K39/385 , A61K39/44 , A61K38/18 , A61K38/19 , A61K38/20 , A61K38/21 , A61K38/22
CPC分类号： A61K47/48438 , A61K31/00 , A61K38/00 , A61K47/48415 , A61K47/48484 , A61K47/485 , A61K47/48538 , A61K47/48546 , A61K47/48561 , A61K47/48569 , A61K47/6811 , A61K47/6817 , A61K47/6829 , A61K47/6833 , A61K47/6843 , A61K47/6845 , A61K47/6849 , A61K47/6851 , A61K2039/505 , B82Y5/00 , B82Y10/00 , B82Y15/00 , C07K14/475 , C07K16/18 , C07K16/22 , C07K16/28 , C07K16/2803 , C07K16/2833 , C07K16/2851 , C07K16/2863 , C07K16/2881 , C07K16/2887 , C07K16/2896 , C07K16/3007 , C07K16/3092 , C07K16/32 , C07K2317/31 , C07K2317/55 , C07K2317/76 , C07K2319/30 , C07K2319/35 , C07K2319/70 , C07K2319/74 , C12N9/12 , C12N9/22 , C12N9/96 , C12Y207/11001 , G01N33/54353 , G01N33/588 , Y02A50/491
摘要： The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition.
摘要翻译：本发明涉及用于制备和使用具有多种功能和/或结合特异性的限定组合物的生物活性组合物的方法和组合物。在特定的实施方案中，生物活性组件使用对接和锁定（DNL）方法形成，其利用二聚化和对接结构域（DDD）和锚定结构域（AD）之间的特异性结合相互作用形成组件。在各种实施方案中，一个或多个效应物可以连接到DDD或AD序列。互补AD或DDD序列可以连接到形成生物活性组件核心的适配器模块，从而允许通过特定的DDD / AD结合相互作用形成组装体。这些组合物可以连接到各种各样的效应部分，用于治疗，检测和/或诊断疾病，病原体感染或其他医学或兽医病症。

70. 发明申请

US20090202433A1 Methods and Compositions for Generating Bioactive Assemblies of Increased Complexity and Uses 有权
标题翻译：用于生成增加复杂性和用途的生物活性组件的方法和组合
公开(公告)号：US20090202433A1
公开(公告)日：2009-08-13
申请号：US12417917
申请日：2009-04-03
申请人： Chien-Hsing Chang , David M. Goldenberg , William J. McBride , Edmund A. Rossi
发明人： Chien-Hsing Chang , David M. Goldenberg , William J. McBride , Edmund A. Rossi
IPC分类号： A61K51/10 , A61K49/00 , A61K9/127 , A61K38/20 , A61K39/395 , A61K38/12
CPC分类号： A61K47/48438 , A61K31/00 , A61K38/00 , A61K47/48415 , A61K47/48484 , A61K47/485 , A61K47/48538 , A61K47/48546 , A61K47/48561 , A61K47/48569 , A61K47/6811 , A61K47/6817 , A61K47/6829 , A61K47/6833 , A61K47/6843 , A61K47/6845 , A61K47/6849 , A61K47/6851 , A61K2039/505 , B82Y5/00 , B82Y10/00 , B82Y15/00 , C07K14/475 , C07K16/18 , C07K16/22 , C07K16/28 , C07K16/2803 , C07K16/2833 , C07K16/2851 , C07K16/2863 , C07K16/2881 , C07K16/2887 , C07K16/2896 , C07K16/3007 , C07K16/3092 , C07K16/32 , C07K2317/31 , C07K2317/55 , C07K2317/76 , C07K2319/30 , C07K2319/35 , C07K2319/70 , C07K2319/74 , C12N9/12 , C12N9/22 , C12N9/96 , C12Y207/11001 , G01N33/54353 , G01N33/588 , Y02A50/491
摘要： The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition.
摘要翻译：本发明涉及用于制备和使用具有多种功能和/或结合特异性的限定组合物的生物活性组合物的方法和组合物。在特定的实施方案中，生物活性组件使用对接和锁定（DNL）方法形成，其利用二聚化和对接结构域（DDD）和锚定结构域（AD）之间的特异性结合相互作用形成组件。在各种实施方案中，一个或多个效应物可以连接到DDD或AD序列。互补AD或DDD序列可以连接到形成生物活性组件核心的适配器模块，从而允许通过特定的DDD / AD结合相互作用形成组装体。这些组合物可以连接到各种各样的效应部分，用于治疗，检测和/或诊断疾病，病原体感染或其他医学或兽医病症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式